Catalyst Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Catalyst Pharmaceuticals (CPRX) Tops Q3 EPS by 2c, Offers FY19 and FY20 Guidance
November 12, 2019 4:41 PM ESTCatalyst Pharmaceuticals (NASDAQ: CPRX) reported Q3 EPS of $0.13, $0.02 better than the analyst estimate of $0.11. Revenue for the quarter came in at $30.9 million versus the consensus estimate of $33.18 million.
GUIDANCE:
Catalyst Pharmaceuticals sees FY2019 revenue of $100 million, versus the consensus of $111... More
